You are here: Industry Insights > Capsida

News List

Capsida Unveils Next-Generation Gene Therapy Manufacturing contractpharma
July 28, 2021
New 15,000 square foot facility in Thousand Oaks will enable end-to-end gene therapy manufacturing capability.
Capsida Biotherapeutics Opens Facility in Thousand Oaks contractpharma
July 26, 2021
New 15,000 square-foot facility will enable industry leading end-to-end gene therapy manufacturing capability.
CRISPR, Capsida team up on gene-edited therapies for ALS, Friedreich's ataxia firstwordpharma
June 16, 2021
CRISPR Therapeutics has inked a partnership with newly launched Capsida Biotherapeutics to develop and commercialise in vivo gene-editing therapies delivered with engineered adeno-associated virus (AAV) vectors for the treatment of familial amyotrophic
Capsida Biotherapeutics Appoints CMO contractpharma
May 13, 2021
Capsida Biotherapeutics Inc., a biotechnology company developing targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering platform, has appointed Swati Tole, M.D., as chief medical officer. Dr. Tole brings extensive ...